These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 17440631)

  • 21. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
    Song H; Du Y; Sgouros G; Prideaux A; Frey E; Wahl RL
    J Nucl Med; 2007 Jan; 48(1):150-7. PubMed ID: 17204712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma.
    Santos ES; Kharfan-Dabaja MA; Ayala E; Raez LE
    Leuk Lymphoma; 2006 Dec; 47(12):2453-76. PubMed ID: 17169792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma.
    Gregory SA; Hohloch K; Gisselbrecht C; Tobinai K; Dreyling M
    Oncologist; 2009; 14 Suppl 2():4-16. PubMed ID: 19819920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin).
    Hernandez MC; Knox SJ
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):6-10. PubMed ID: 14710397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
    DeNardo GL; DeNardo SJ; O'Donnell RT; Kroger LA; Kukis DL; Meares CF; Goldstein DS; Shen S
    Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
    Friedberg JW; Fisher RI
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):18-26. PubMed ID: 14748653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New strategies in radioimmunotherapy for lymphoma.
    Pandit-Taskar N; Hamlin PA; Reyes S; Larson SM; Divgi CR
    Curr Oncol Rep; 2003 Sep; 5(5):364-71. PubMed ID: 12895386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioimmunotherapy of Non-Hodgkin's lymphoma.
    Britton KE
    J Nucl Med; 2004 May; 45(5):924-5. PubMed ID: 15136647
    [No Abstract]   [Full Text] [Related]  

  • 29. Whither Radioimmunotherapy: To Be or Not To Be?
    Green DJ; Press OW
    Cancer Res; 2017 May; 77(9):2191-2196. PubMed ID: 28428282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Dillman RO
    Curr Hematol Rep; 2003 Jan; 2(1):30-7. PubMed ID: 12901152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma.
    Scheidhauer K; Wolf I; Baumgartl HJ; Von Schilling C; Schmidt B; Reidel G; Peschel C; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1276-82. PubMed ID: 12271407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cure of incurable lymphoma.
    DeNardo GL; Sysko VV; DeNardo SJ
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S46-56. PubMed ID: 16979440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody.
    Decaudin D; Levy R; Lokiec F; Morschhauser F; Djeridane M; Kadouche J; Pecking A
    Anticancer Drugs; 2007 Jul; 18(6):725-31. PubMed ID: 17762404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibodies conjugated with radioisotopes for the treatment of Non-Hodgkin's lymphoma.
    Bush S
    Semin Oncol Nurs; 2002 Feb; 18(1 Suppl 1):16-21. PubMed ID: 11878047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma.
    Multani P
    Int J Hematol; 2002 Dec; 76(5):401-10. PubMed ID: 12512834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretargeted radioimmunotherapy (PRIT) using an antibody-streptavidin fusion protein in non-Hodgkin's lymphoma.
    Weiden PL
    Leuk Lymphoma; 2002 Oct; 43(10):1971-3. PubMed ID: 12481894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current status of cancer therapy with radiolabeled monoclonal antibody.
    Oriuchi N; Higuchi T; Hanaoka H; Iida Y; Endo K
    Ann Nucl Med; 2005 Jul; 19(5):355-65. PubMed ID: 16164191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioimmunotherapy for Non-Hodgkin's Lymphoma.
    Rao AV; Akabani G; Rizzieri DA
    Clin Med Res; 2005 Aug; 3(3):157-65. PubMed ID: 16160070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A clinical and scientific overview of tositumomab and iodine I 131 tositumomab.
    Zelenetz AD
    Semin Oncol; 2003 Apr; 30(2 Suppl 4):22-30. PubMed ID: 12728404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.